Case of neuromyelitis optica: bilateral sensorineural hearing loss and transverse myelopathy following intrathecal chemotherapy.
Sergio Andrés Castillo-TorresCarlos A Soto-RincónHéctor J Villarreal-MontemayorBeatriz Chávez-LuévanosPublished in: BMJ case reports (2020)
Neurotoxicity from intrathecally administered chemotherapeutic drugs is frequent, particularly with some agents like methotrexate, which are more prone to developing adverse effects. Myelopathy ranks among the most frequently reported neurological entities; with the diagnosis being straightforward, after ruling out infectious, metabolic, autoimmune or paraneoplastic causes. Scarcity of cases precludes evidence-based recommendations for the management of these complications. The most common therapeutic approach consists of the suspension of chemotherapy, exclusion of infectious and neoplastic causes, with prompt administration of high-dose steroids. We report a 21-year-old patient with acute lymphoblastic leukaemia, who developed acute transverse myelitis and bilateral sensorineural hearing loss, after five rounds of intrathecal methotrexate and cytarabine. Although neurotoxicity from both agents has been documented, this combination has not been previously reported.
Keyphrases
- high dose
- liver failure
- drug induced
- stem cell transplantation
- low dose
- spinal cord
- case report
- respiratory failure
- locally advanced
- aortic dissection
- acute myeloid leukemia
- multiple sclerosis
- hepatitis b virus
- squamous cell carcinoma
- spinal cord injury
- rectal cancer
- brain injury
- intensive care unit
- chemotherapy induced
- blood brain barrier